Vivos Therapeutics, Inc.

Stage 4 · Declining · week 50

As of Oct 22, 2026, Vivos Therapeutics is in Stage 4, the downtrend phase, now in week 50 (since Oct 24, 2025). It closed at $0.13, 95.6% below its 52-week high and below its 200-day average, which is falling.

$0.13

-1.48% today

$4.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VVOS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 22w

S1 19w

S4 52w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 15w → S1 3w → S2 8w → S3 1w → S4 22w → S1 19w → S2 12w → S3 6w → S4 11w → S1 3w → S2 9w → S3 4w → S4 52w current

Total tracked: 165 weeks across 13 stage runs.

VVOS among Medical Devices126th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…126	VVOSVivos Therapeutics, Inc.	Stage 4 · wk 50	5	−10.7%

vs 52W High

-95.6%

$0.13 lo$3.01 hi

95.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 50

1w13w26w

Week 50, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-83.4%

200 DMA: $0.80 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.10x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.7%

-66.2%

-85.2%

YTD

-94.7%

-95.2%

Scan Membership

Breakout Watch

Latest: 2024-12-09

3 appearances in last 60 days. First seen: 2023-03-15.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 50 · Vol 0.10x

2026-10-21S4

Wk 50 · Vol 0.26x

2026-10-20S4

Wk 50 · Vol 4.63x

2026-10-19S4

Wk 50 · Vol 3.03x

2026-10-16S4

Wk 50 · Vol 0.10x

2026-10-15S4

Wk 49 · Vol 0.75x

2026-10-14S4

Wk 49 · Vol 0.04x

2026-10-13S4

Wk 49 · Vol 0.05x

2026-10-12S4

Wk 49 · Vol 0.03x

2026-10-09S4

Wk 49 · Vol 0.55x

2026-10-08S4

Wk 48 · Vol 0.12x

2026-10-07S4

Wk 48 · Vol 0.03x

Moving averages & range

50 DMA

$0.19

200 DMA

$0.80

52W High

$3.01

52W Low

$0.13

5D Low

$0.13

Resistance levels (recent highs)

20d High

$0.15

60d High

$0.46

120d High

$0.87

250d High

$3.01

Next resistance

+15.8%

to 20d High

ROE

-8585.3%

Profit margin -121.8%

Dividend Yield

0.00%

P/B -0.4

Vivos Therapeutics: quick answers

What stage is Vivos Therapeutics in?

As of Oct 22, 2026, Vivos Therapeutics (VVOS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 24, 2025 and is in week 50. What the four stages mean

Is Vivos Therapeutics in an uptrend?

No. Vivos Therapeutics is in a Stage 4 downtrend. It trades 83.4% below its 200-day average, which is falling.

How far is Vivos Therapeutics from its 52-week high?

Vivos Therapeutics closed at $0.13 on Oct 22, 2026, 95.6% below its 52-week high of $3.01. Its 52-week low is $0.13.

How has Vivos Therapeutics performed over the past year?

As of Oct 22, 2026, Vivos Therapeutics is down 95.2% over the past year and down 94.7% so far in 2026.

Which sector and industry is Vivos Therapeutics in?

Vivos Therapeutics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.